Gilead Gets Analyst Upgrade on 'Outstanding' HIV Treatment Data

By Andrew Kessel
Updated July 08, 2024
12:05 PM EDT
The Gilead headquarters in Foster City, California, on Jan. 29, 2024

David Paul Morris / Bloomberg via Getty Images

Key Takeaways

  • Raymond James analysts upgraded Gilead Sciences stock to "outperform" from "market perform."
  • The upgrade was driven by Gilead's drug lenacapavir, which showed a 100% effectiveness rate in preventing HIV infection in women.
  • Lenacapavir and PBC treatment seladelpar could see combined annual sales of $3.7 billion by 2030, according to Raymond James' model.


Gilead Sciences (GILD) shares climbed in intraday trading Monday after Raymond James analysts upgraded the drug developer to “outperform” from “market perform.”

The firm issued a price target of $93, a nearly 40% premium to Friday’s closing price of $66.69. Gilead shares were up 0.6% around midday Monday but are down about 15% this year. 

Raymond James Notes 'Outstanding Data' From Lenacapavir Phase 3 Trial

Raymond James pointed to “outstanding data” from a Phase 3 trial of Gilead’s injectable HIV treatment lenacapavir, which showed a 100% effectiveness rate in preventing HIV infection in women. Gilead is expected to launch lenacapavir in late 2025, assuming success in its next study. 

The firm also cited the potential Food and Drug Administration (FDA) approval of seladelpar for the treatment of primary biliary cholangitis (PBC), a chronic autoimmune disease affecting the liver. Together, the two treatments could generate $3.7 billion in combined annual sales by 2030, according to Raymond James’ model.

Do you have a news tip for Investopedia reporters? Please email us at
Article Sources
Investopedia requires writers to use primary sources to support their work. These include white papers, government data, original reporting, and interviews with industry experts. We also reference original research from other reputable publishers where appropriate. You can learn more about the standards we follow in producing accurate, unbiased content in our editorial policy.

  1. Raymond James. “Upgrading to Outperform; PrEP and PBC Are Growth Drivers in 'Areas of Expertise' (HIV, Liver).”

Take the Next Step to Invest
×
The offers that appear in this table are from partnerships from which Investopedia receives compensation. This compensation may impact how and where listings appear. Investopedia does not include all offers available in the marketplace.